Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Fig. 2

Efficacy outcomes after switching from ADA→tofacitinib 5 mg BID according to Phase 3 ADA response. Efficacy outcomes for patients in the ADA→tofacitinib 5 mg BID group are shown following switch to tofacitinib in the LTE study according to ADA response in the Phase 3 study. aFigure excludes one patient in the ADA→tofacitinib 5 mg BID group who had a missing response to ADA at the Phase 3 last visit and no response to tofacitinib at the month 3 LTE. bIn patients with baseline HAQ-DI ≥ 0.35. cFigure excludes one patient in the ADA→tofacitinib 5 mg BID group who had a missing response to ADA at the Phase 3 last visit and a response to tofacitinib at the month 3 LTE. ACR20: ≥ 20% improvement in American College of Rheumatology response criteria, ADA: adalimumab, BID: twice daily, HAQ-DI: Health Assessment Questionnaire-Disability Index, LTE: long-term extension, MDA: minimal disease activity, n: number of patients in category, P3: Phase 3, PASDAS: Psoriatic Arthritis Disease Activity Score, PASI75: ≥ 75% Psoriasis Area and Severity Index improvement from baseline

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us